smokers (p 0.05). SOD and TAC important boost following 1, two, and three weeks compared with baseline in smokers (p 0.05). 40 mg/day: MDA and ISP substantially reduced after 1, 2, and three weeks compared with baseline in smokers (p 0.05). SOD and TAC considerable boost soon after 2 and three weeks compared with baseline in smokers (p 0.05) 6 mg/day: reduction in total phospholipid hydroperoxides (PLOOH) right after 12 weeks compared with baseline (p 0.01) and compared with placebo (p 0.05). Decreased phosphatidyl-ethanolamine hydroperoxide (PEOOH) just after 12 weeks compared with baseline (p 0.05) and compared with placebo (p 0.05). 12 mg/day: 48 reduction in total PLOOH right after 12 weeks compared with baseline (p 0.01) and 35 much less total PLOOH at 12 weeks compared with all the manage group (p 0.05). The 12 mg/day group had 46 much less phosphatidylcholine hydroperoxide (PCOOH) at 12 weeks compared with baseline (p 0.01). Comparing using the handle group, MDA contents within the test group decreased significantly (p 0.01), and SOD and GSH-Px activities enhanced substantially (p 0.01).Choi, H.D. et al., 2011 [40]Bcl-xL Inhibitor custom synthesis Randomized, double-blind, placebo-controlled, prospective study27 overweight subjects0, 20 mg/day12 weeksHashimoto H. et al., 2011 [41]Open-label, potential study35 cataract patients6 mg/day2 weeksKim, J.H. et al., 2011 [42]Randomized, Repeated, measured, potential study39 heavy smokers, 39 non-smokers0, 5, 20, or 40 mg/day3 weeksNakagawa K. et al., 2011 [43]Randomized, double-blind, placebo-controlled, potential study30 healthier subjects0, six, 12 mg/day12 weeksPeng L. et al., 2011 [44]Randomized, placebo-controlled study115 healthful subjects0, 40 mg/day90 daysNutrients 2022, 14,7 ofTable 1. Cont. Author/Year/Reference Study Design Randomized, double-blind, placebo-controlled, prospective study Open-label, potential study Open-label, prospective study Randomized, double-blind, placebo-controlled, prospective study Randomized, double-blind, placebo-controlled, potential study Subjects Dose Duration Outcome 2 mg/day: Concentrations of plasma 8-hydroxy-2 -deoxyguanosine lowered following four weeks and eight weeks compared with placebo (p 0.05). eight mg/day: Concentrations of plasma 8-hydroxy-2 -deoxyguanosine decreased right after four weeks and eight weeks compared with placebo (p 0.05) Increased blood biological antioxidant prospective (BAP; +4.6 , p 0.05) Reduced protein oxidation (-10 , p 0.05)Park J.S. et al., 2010 [45]42 KDM4 Inhibitor Synonyms healthy subjects2 or 8 mg/day8 weeksIwabayashi M. et al., 2009 [46] Yamada T. et al., 2010 [47] Fassett, R.G. et al., 2008 [48]35 healthful subjects (with higher oxidative stress) 6 wholesome subjects and six Sjoegren’s syndrome subjects 58 renal transplant recipients12 mg/day 12 mg/day8 weeks 2 weeks0, 12 mg/day12 monthsTotal plasma F2-isoprostanes lowered by 23.0 in placebo and 29.7 in AX groups (N.S.)Karppi, J. et al., 2007 [49]39 healthy subjects0, eight mg/day3 monthsDecreased oxidation of fatty acids in healthier males (p 0.05)Kim Y.K. et al., 2004 [50]Open-label, potential study15 wholesome postmenopausal women0, two, eight mg/day8 weeksDecreased plasma TBARS levels: two mg group from 1.42 0.18 to 1.13 0.18 nM/mg (p 0.05). eight mg AX group from 1.62 0.14 nM/mg to 1.13 0.12 nM/mg just after eight weeks (p 0.05). Elevated TAS from 0.85 0.42 mM/L to 1.90 0.58 mM/L within the 8 mg group. Urinary 8-isoprostanes excretion didn’t reduce substantially. (See Table three for other outcomes.) As well as AX, other nutrients for instance antioxidants were applied within the study.Nutrients 2022, 14,8 o